<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01021956</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN905 MLT202</org_study_id>
    <nct_id>NCT01021956</nct_id>
  </id_info>
  <brief_title>Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD</brief_title>
  <official_title>A Phase IIa, Safety and Preliminary Effects Study of WST11 (Stakel®) Mediated Vascular-Targeted Photodynamic (VTP) Therapy in Subjects With Choroidal Neovascularization (CNV) Associated With Age-Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steba Biotech S.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steba Biotech S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the safety(first objective) and efficacy(second
      objective)of an experimental drug product,Stakel®, in the treatment of neovascular Age
      related Macular Degeneration (AMD). The drug product is activated in patients by exposure to
      light at a specific wavelength (&quot;Vascular Targeted Photodynamic therapy&quot;, &quot;VTP&quot;). The
      exploratory objective is to assess whether it is possible to delay or reduce the requirement
      for anti Vascular Endothelium Growth Factor (anti VEGF) intravitreal therapy in the first 12
      weeks after VTP.

      All subjects will have a 52 weeks safety follow up telephone call (Not for Adverse Events
      (AEs) collection).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this Phase IIa clinical study is to evaluate the safety of treatment
      with Stakel®-mediated VTP in subjects with neovascular AMD. The secondary objective of this
      Phase IIa clinical study is to explore the effect of treatment with Stakel®-mediated VTP in
      subjects with neovascular AMD. The exploratory objective is to assess whether it is possible
      to delay or reduce the requirement for anti Vascular Endothelium Growth Factor (anti VEGF)
      intravitreal therapy in the first 12 weeks after VTP.

      All subjects will have a 52 weeks safety follow up telephone call. (Not for AEs collection).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Retinal vascular occlusion in 2 patients
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs) - Number of Subjects With Eye Disorders</measure>
    <time_frame>12 week follow-up</time_frame>
    <description>Adverse events (AEs) consisting in Eye disorders, related or non related were collected throughout the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>Week 12.</time_frame>
    <description>Variation from baseline to week 12 in visual acuity score using Early Treatment Diabetic Retinopathy Study (ETDRS) 4.0 meter distance acuity chart.
The patient is asked to read letter on a board from a distance of 4 meters. The charts use a geometric progression in letter size from line to line. The scores range from 0 (worse outcome) to 100/100 (best outcome)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Macular Degeneration</condition>
  <condition>Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>WST11 (STAKEL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single doses of 2.5 mg/kg of STAKEL® in combination with transpupilar illumination of the macula at escalating doses from 12.5 to 75 Joules/cm².</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STAKEL</intervention_name>
    <description>Open-label,safety and exploratory efficacy study in subjects with active CNV followed for 12 weeks.During first stage(dose escalating stage) subjects assigned to group 1 to 4 will receive a single treatment of VTP at one of three light levels and one of two Drug Light Interval (DLI).Second stage(dose confirmation)will be only initiated at a dose level in which an effect has been seen at week 1 and there is a maximum of one Dose Limiting Toxicity (DLT) out of three subject at week 5.</description>
    <arm_group_label>WST11 (STAKEL)</arm_group_label>
    <other_name>WST11</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Twenty eight days or more after at least one ranibizumab injection, recurrent leakage
             on Fluorescein Angiography (FA) from subfoveal Choroidal NeoVessels (CNV) secondary to
             AMD.

          -  Total lesion size not exceeding 5400 μm in its greatest linear dimension.

          -  Best Corrected Visual Acuity (BCVA) letter score of 73 to 23 in the study eye at a
             starting distance of 4 meters.

          -  No contraindication to intravitreal ranibizumab injection.

          -  Postmenopausal for at least 12 months prior to enrollment or practicing medically
             acceptable form of birth control and not pregnant. Male subjects must be practicing a
             medically acceptable form of birth control.

        Exclusion Criteria:

          -  Prior treatments:

               -  Previous subfoveal laser photocoagulation, external-beam radiation therapy, or
                  transpupillary thermoTherapy (TTT) in the study eye at any time.

               -  Using anti-VEGF therapies for other indications (e.g., cancer) in the 30 days
                  prior to the study and/or during the study

               -  Received anti-VEGF injection in study eye during less than 28 days prior to Day 1
                  of the study.

               -  More than three previous photodynamic therapy (PDT) treatments in the preceding
                  12 months.

               -  Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within the
                  preceding month.

               -  History of vitrectomy,of glaucoma filtering surgery,submacular surgery or other
                  surgical intervention in the study eye.

               -  History of corneal transplant in the study eye.

               -  Previous participation in any studies of investigational drugs within 1 month
                  preceding Day 1 (excluding vitamins and minerals).

          -  Lesion Characteristics

               -  Permanent structural damage to the center of the fovea of the study eye, or a
                  concurrent ocular or systemic condition that could contraindicate administration
                  of an investigational drug, or render the subject at a high risk of treatment
                  complications.

               -  Subretinal hemorrhage in the study eye that involves the center of the fovea, if
                  the size of the hemorrhage is either ≥50% of the total lesion area or ≥1 disc
                  area in size.

               -  Subfoveal fibrosis or atrophy in the study eye which is at least 50% of the
                  lesion.

               -  CNV in either eye due to other causes.

               -  Retinal pigment epithelial tear involving the macula in the study eye.

          -  Concurrent Ocular Conditions

               -  Active intraocular inflammation (grade trace or above) or current vitreous
                  hemorrhage or rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in
                  the study eye.

               -  History of idiopathic or autoimmune-associated uveitis in either eye.

               -  Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either
                  eye.

               -  Aphakia or absence of the posterior capsule in the study eye.

               -  Spherical equivalent of the refractive error in the study eye demonstrating
                  more-than eight diopters of myopia.

               -  Intraocular surgery (including cataract surgery) in the study eye within three
                  months preceding Day 1.

               -  Uncontrolled glaucoma in the study eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Bressler, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor Gonzalez, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Valley Retina Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Wells, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Palmetto Retina Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francine Behar Cohen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hotel Dieu Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adrienne Scott, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins/ Wilmer Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins,Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Retina Center</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de Paris Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>November 29, 2009</study_first_submitted>
  <study_first_submitted_qc>November 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2009</study_first_posted>
  <results_first_submitted>April 20, 2016</results_first_submitted>
  <results_first_submitted_qc>September 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2018</results_first_posted>
  <last_update_submitted>September 13, 2018</last_update_submitted>
  <last_update_submitted_qc>September 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular Degeneration</keyword>
  <keyword>Age Related Macular Degeneration</keyword>
  <keyword>Choroidal Neovascularization</keyword>
  <keyword>AMD</keyword>
  <keyword>CNV</keyword>
  <keyword>WST11</keyword>
  <keyword>Stakel</keyword>
  <keyword>Photodynamic therapy</keyword>
  <keyword>Vascular Targeted Photodynamic therapy</keyword>
  <keyword>VTP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data are available in case report form for each patient</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1a -2.5 mg/kg STAKEL - 25 J/cm²</title>
          <description>2.5 mg/kg dose of STAKEL - 25 Joules/cm² of laser light at 753 nm</description>
        </group>
        <group group_id="P2">
          <title>Group 1b-2.5 mg/kg STAKEL - 12.6 J/cm²</title>
          <description>2.5 mg/kg dose of STAKEL -12.6 Joules/cm² of laser light at 753 nm</description>
        </group>
        <group group_id="P3">
          <title>Group 1c-2.5 mg/kg STAKEL - 18.9 J/cm²</title>
          <description>2.5 mg/kg dose of STAKEL -18.9 Joules/cm² of laser light at 753 nm</description>
        </group>
        <group group_id="P4">
          <title>Group 2-2.5 mg/kg STAKEL - 50 J/cm²</title>
          <description>2.5 mg/kg dose of STAKEL - 50 Joules/cm² of laser light at 753 nm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1a</title>
          <description>2.5 mg/kg - 25 Joules/cm²</description>
        </group>
        <group group_id="B2">
          <title>Group 1b</title>
          <description>2.5 mg/kg - 12.6 Joules/cm²</description>
        </group>
        <group group_id="B3">
          <title>Group 1c</title>
          <description>2.5 mg/kg - 18.9 Joules/cm²</description>
        </group>
        <group group_id="B4">
          <title>Group 2</title>
          <description>2.5 mg/kg - 50 Joules/cm²</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.30" spread="7.51"/>
                    <measurement group_id="B2" value="78.3" spread="6.11"/>
                    <measurement group_id="B3" value="81.00" spread="6.08"/>
                    <measurement group_id="B4" value="87.00" spread="0"/>
                    <measurement group_id="B5" value="77.60" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events (AEs) - Number of Subjects With Eye Disorders</title>
        <description>Adverse events (AEs) consisting in Eye disorders, related or non related were collected throughout the study.</description>
        <time_frame>12 week follow-up</time_frame>
        <population>The safety analysis set included all subjects with a signed informed consent form who received study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1a</title>
            <description>2.5 mg/kg - 25 Joules/cm²</description>
          </group>
          <group group_id="O2">
            <title>Group 1b</title>
            <description>2.5 mg/kg - 12.6 Joules/cm²</description>
          </group>
          <group group_id="O3">
            <title>Group 1c</title>
            <description>2.5 mg/kg - 18.9 Joules/cm²</description>
          </group>
          <group group_id="O4">
            <title>Group 2</title>
            <description>2.5 mg/kg - 50 Joules/cm²</description>
          </group>
          <group group_id="O5">
            <title>Overall</title>
            <description>All doses of TOOKAD Soluble and Laser Light</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (AEs) - Number of Subjects With Eye Disorders</title>
          <description>Adverse events (AEs) consisting in Eye disorders, related or non related were collected throughout the study.</description>
          <population>The safety analysis set included all subjects with a signed informed consent form who received study treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity</title>
        <description>Variation from baseline to week 12 in visual acuity score using Early Treatment Diabetic Retinopathy Study (ETDRS) 4.0 meter distance acuity chart.
The patient is asked to read letter on a board from a distance of 4 meters. The charts use a geometric progression in letter size from line to line. The scores range from 0 (worse outcome) to 100/100 (best outcome)</description>
        <time_frame>Week 12.</time_frame>
        <population>Although STAKEL® VTP procedure induced effective neovessels occlusion in some patients, as observed in the previous study (study MLT 2.01 ), due to the small number of patients treated and the early termination of the study, limited efficacy data is available and no efficacy conclusion can be drown from this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1a</title>
            <description>2.5 mg/kg - 25 Joules/cm²</description>
          </group>
          <group group_id="O2">
            <title>Group 1b</title>
            <description>2.5 mg/kg - 12.6 Joules/cm²</description>
          </group>
          <group group_id="O3">
            <title>Group 1c</title>
            <description>2.5 mg/kg - 18.9 Joules/cm²</description>
          </group>
          <group group_id="O4">
            <title>Group 2</title>
            <description>2.5 mg/kg - 50 Joules/cm²</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>Variation from baseline to week 12 in visual acuity score using Early Treatment Diabetic Retinopathy Study (ETDRS) 4.0 meter distance acuity chart.
The patient is asked to read letter on a board from a distance of 4 meters. The charts use a geometric progression in letter size from line to line. The scores range from 0 (worse outcome) to 100/100 (best outcome)</description>
          <population>Although STAKEL® VTP procedure induced effective neovessels occlusion in some patients, as observed in the previous study (study MLT 2.01 ), due to the small number of patients treated and the early termination of the study, limited efficacy data is available and no efficacy conclusion can be drown from this study.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-20" upper_limit="22"/>
                    <measurement group_id="O2" value="-12" lower_limit="-12" upper_limit="0"/>
                    <measurement group_id="O3" value="4" lower_limit="-7" upper_limit="7"/>
                    <measurement group_id="O4" value="-33" lower_limit="-33" upper_limit="-33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants With Any Ocular or Non-ocular Adverse Events</title>
        <description>Global safety assessment including record of all complications and AEs, loss of lines in BCVA, slit lamp findings, IOP(Intra Occular Pressure), and fundus findings. All ocular and non-ocular AEs must be assessed for severity and relationship to the investigational product. Of note: the primary end point only concern patient with eye disorders events.</description>
        <time_frame>Day 1;Week 1;Week 5;Week 12.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1a</title>
            <description>2.5 mg/kg - 25 Joules/cm²</description>
          </group>
          <group group_id="O2">
            <title>Group 1b</title>
            <description>2.5 mg/kg - 12.6 Joules/cm²</description>
          </group>
          <group group_id="O3">
            <title>Group 1c</title>
            <description>2.5 mg/kg - 18.9 Joules/cm²</description>
          </group>
          <group group_id="O4">
            <title>Group 2</title>
            <description>2.5 mg/kg - 50 Joules/cm²</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Ocular or Non-ocular Adverse Events</title>
          <description>Global safety assessment including record of all complications and AEs, loss of lines in BCVA, slit lamp findings, IOP(Intra Occular Pressure), and fundus findings. All ocular and non-ocular AEs must be assessed for severity and relationship to the investigational product. Of note: the primary end point only concern patient with eye disorders events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>systematic Assessment : Regular investigator assessment</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1A</title>
          <description>2.5 mg/kg - 25 Joules/cm²</description>
        </group>
        <group group_id="E2">
          <title>Group 1B</title>
          <description>2.5 mg/kg - 12.6 Joules/cm²</description>
        </group>
        <group group_id="E3">
          <title>Group 1C</title>
          <description>2.5 mg/kg - 18.9 Joules/cm²</description>
        </group>
        <group group_id="E4">
          <title>Group 2</title>
          <description>2.5 mg/kg - 50 Joules/cm²</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>retinal vascular occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">eye pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Visual Acuty reduced</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Retinal pigment epitheliopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>macular ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Retinal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bertrand Gaillac International Project Leader</name_or_title>
      <organization>STEBA Biotech</organization>
      <phone>+33 9 74 19 79 05</phone>
      <email>b.gaillac@stebabiotech.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

